FDA calendar · April 2023 · built from SEC filings

PDUFA dates April 2023: FDA calendar and catalysts.

Updated Snapshot 20261116T222116ZBuilt

0 PDUFA dates fell in April 2023. The FDA calendar also recorded 27 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

PDUFA dates in April 2023

No PDUFA dates are disclosed for this period as of November 16, 2026.

Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months

April 2023: other FDA decisions and filings

DateDrugCompanyEventIndicationStatusSource
Apr 2023Month disclosedTransConASNDComplete Response Letter—CRL issuedSEC Form 10-K
Apr 2023Month disclosedSER-109IMRNFDA approval—ApprovedSEC 8-K Exhibit 99.1
Apr 2023Month disclosedSER-155MCRBFDA approval—ApprovedSEC 8-K Exhibit 99.1
Apr 2023Month disclosedHyBryte (lymphoma)SNGXNDA/BLA submission—CompletedSEC Form 10-Q
April 14, 2023Lupron Depot (leuprolide acetate)ABBVLabel expansion—ApprovedopenFDA Drugs@FDA
April 17, 2023Qulipta (atogepant)ABBVLabel expansion—ApprovedopenFDA Drugs@FDA
April 19, 2023ENTADFI® (finasteride-tadalafil)VERUFDA approval—ApprovedSEC Form 10-Q
April 24, 2023Alhemo (concizumab-mtci)NVOComplete Response Letter—CRL issuedFDA Complete Response Letters
April 25, 2023QALSODY (tofersen)BIIBFDA approvalTo treat amyotrophic lateral sclerosis in adults who have a SOD1 gene mutationApprovedFDA Novel Drug Approvals
April 26, 2023ZEJULA (niraparib)GSKFDA approval—ApprovedopenFDA Drugs@FDA
April 26, 2023ZEJULA (niraparib)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
April 26, 2023Trikafta (Copackaged) (elexacaftor, ivacaftor, tezacaftor; ivacaftor)VRTXFDA approval—ApprovedopenFDA Drugs@FDA
April 27, 2023roluperidone (MIN-101)NERVNDA/BLA submissionnegative symptoms in patients with schizophreniaCompletedSEC Form 10-K
April 28, 2023Symbicort Aerosphere (budesonide; formoterol fumarate)AZNFDA approval—ApprovedopenFDA Drugs@FDA
April 28, 2023LYNPARZA® (olaparib)AZNAdvisory committee—PositiveFDA advisory committee calendar
April 28, 2023roluperidone (MIN-101)NERVNDA/BLA accepted—CompletedSEC Form 10-Q
April 28, 2023Sogroya (somapacitan-beco)NVOLabel expansion—ApprovedopenFDA Drugs@FDA
April 28, 2023Libtayo (cemiplimab-rwlc)REGNLabel expansion—ApprovedopenFDA Drugs@FDA
April 28, 2023UZEDY (risperidone)TEVAFDA approvalschizophrenia in adultsApprovedSEC 8-K Exhibit 99.1

April 2023: dated readouts

DateDrugCompanyEventIndicationStatusSource
Apr 2023Month disclosedmivelsiranALNYInterim readoutearly-onset AD, and in April 2023 and July 2023, we reported positive interim resultsPositiveSEC Form 10-K

April 2023: trial starts and primary completions

DateDrugCompanyEventIndicationStatusSource
Apr 2023Month disclosedGLPG3667LKFTTrial start—CompletedSEC Form 10-K
Apr 2023Month disclosedcertepetideLSTATrial start—CompletedSEC 8-K Exhibit 99.1
Apr 2023Month disclosedmivelsiranALNYTrial startearly-onset AD, and in April 2023 and July 2023, we reported positive interim resultsCompletedSEC Form 10-K
Apr 2023Month disclosedALZN002ALZNTrial start—CompletedSEC 8-K Exhibit 99.1
Apr 2023Month disclosedRevatio® (sildenafil)DARETrial start—CompletedSEC Form 10-K
Apr 2023Month disclosedbezuclastinib (CGT9486)COGTTrial start—CompletedSEC Form 10-Q
Apr 2023Month disclosedJANX008JANXTrial start—CompletedSEC Form 10-K

Questions

What PDUFA dates are in April 2023?

0 PDUFA dates fell in April 2023. The FDA calendar also recorded 27 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

Can these dates change?

Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.